Tirzepatide has become one of the most talked-about medications in chronic weight management. For adults living with obesity or excess weight, it has shown encouraging results when combined with healthy lifestyle changes and ongoing medical supervision.
Unlike traditional weight management approaches that rely solely on diet and exercise, tirzepatide works by targeting hormones involved in appetite regulation and metabolism, helping many patients feel fuller longer while reducing food intake.
Tirzepatide is a prescription medication administered as a once-weekly injection. It belongs to a newer class of medications that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Together, these hormones help regulate:
By addressing multiple pathways involved in weight regulation, tirzepatide offers a different approach than medications that target only one hormone.
Tirzepatide works by helping people eat less without relying solely on willpower.
Its effects may include:
When combined with a nutritious eating plan and regular physical activity, these effects can support meaningful weight loss for eligible patients.
Clinical studies have demonstrated that tirzepatide can produce significant weight loss in many adults with obesity or overweight when used alongside lifestyle modifications.
Individual results vary based on factors such as:
Healthcare providers monitor progress throughout treatment and adjust care plans based on each patient's individual response.
Many weight management medications work by activating GLP-1 receptors.
Tirzepatide is unique because it activates both:
Researchers believe that targeting both hormone pathways may provide additional metabolic benefits for some patients, including improved appetite regulation and glucose metabolism.
A licensed healthcare provider determines whether tirzepatide is appropriate based on your medical history, current medications and health goals.
It may be considered for adults who meet established medical criteria for chronic weight management.
Treatment is always individualized and should be used as part of a comprehensive medical weight management program.
Tirzepatide is typically started at a lower dose and gradually increased over time to help improve tolerability.
During treatment, patients are encouraged to:
Ongoing monitoring helps providers determine whether treatment continues to be appropriate and effective.
Like all prescription medications, tirzepatide may cause side effects.
The most commonly reported include:
Many side effects improve as the body adjusts to treatment. Patients should contact their healthcare provider if symptoms become severe or persistent.
Tirzepatide may be an option for adults who have struggled to achieve lasting weight loss through lifestyle changes alone.
A licensed healthcare provider can evaluate your medical history, discuss your goals and determine whether tirzepatide or another evidence-based treatment may be appropriate for your individual needs.
Explore Wellness Support Options
Schedule a consultation with a licensed healthcare provider through TeleWellnessMD® to determine whether tirzepatide or another personalized treatment option may be appropriate for your health goals.
This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary. Prescription required.
Sources:
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Jastreboff AM, Garvey WT, Frias JP, et al. Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Trial. Nature Medicine. 2023;29:2909-2918. doi:10.1038/s41591-023-02597-w
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025.